UNSPSC 51334313: Flupentixol dihydrochloride

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C23H25F3N2OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96L0Z069N1, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-, (e)- but more generally known as flupentixol dihydrochloride, which bears US NIH Compound Identifier 5281878.

European Medicines Agency schedules Flupentixol dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02229MIG. Most nations, for tariff and trade purposes, schedule flupentixol dihydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, FLUPENTIXOL DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)/C(=C/CCN3CCN(CC3)CCO)/C4CC(CCC4S2)C(F)(F)F.CL.CL.

UNSPSC 51334313 Flupentixol dihydrochloride is a Commodity code that nominally identifies a single antipsychotic pharmaceutical product, but the recent state and local opportunities tagged under it do not reflect procurement of this specific drug. Instead, the opportunities show state and local jurisdictions procuring a broader range of pharmaceutical products and pharmacy benefit services — including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription program consulting. The mismatch between the code's narrow nominal scope and the actual procurement activity suggests either tagging inconsistency in the issuing systems or that flupentixol dihydrochloride procurement falls under broader pharmaceutical or health service codes in practice. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local governments including Oregon).

Geographically, recent activity spans Florida, Texas, and the Upper Midwest with multistate reach through cooperative purchasing. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic multi-source pharmaceuticals and OTC products with award effective July 1, 2026, using three authorized wholesalers and requiring cGMP certification and Drug Supply Chain Security Act compliance.